The Renin Angiotensin System in Essential Hypertension

ISRCTN	ISRCTN12415112
DOI	https://doi.org/10.1186/ISRCTN12415112
Secondary identifying numbers	N0236102657

Submission date: 29/09/2006
Registration date: 29/09/2006
Last edited: 11/10/2017

Recruitment status: No longer recruiting
Overall study status: Completed
Condition category: Circulatory System

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr David New
Scientific

Blood Pressure Unit
Dept of Physiological Medicine
St George's Hospital Medical School
Cranmer Terrace
London
SW17 0RE
United Kingdom

Study information

Study design	Randomised crossover trial
Primary study design	Interventional
Secondary study design	Randomised cross over trial
Study setting(s)	Hospital
Study type	Treatment
Participant information sheet	Not available in web format, please use the contact details to request a patient information sheet
Scientific title	The Renin Angiotensin System in Essential Hypertension
Study objectives	To determine and compare the effects of enalapril on sodium balance, atrial pressure and the renin angiotensin aldosterone system in humans.
Ethics approval(s)	Not provided at time of registration
Health condition(s) or problem(s) studied	Cardiovascular: Essential hypertension
Intervention	Randomised crossover trial
Intervention type	Other
Primary outcome measure	This research is based on the increasing evidence that blockade of the renin-angiotensin-aldosterone system has benefits additional to a fall in blood pressure. There are two major ways of blocking the renin-angiotensin system (RAS), either by inhibiting the enzyme that generates angiotensin II or by blocking the angiotensin receptor, that medicates most of the actions of angiotensin II on its target tissues. The original and existing aim of this study is to compare the effects of enalapril, an angiotensin converting enzyme inhibitor, against candesartan, a potent and specific angiotensin II receptor blocker, in both normotensive and hypertensive subjects on a normal and moderate sodium restricted diet. Assessment of the contribution of the RAS to blood pressure control and of the mechanism whereby blood pressure falls, will provide important information about the maintenance of blood pressure.
Secondary outcome measures	Not provided at time of registration
Overall study start date	03/12/2001
Completion date	30/09/2005

Eligibility

Participant type(s)	Patient
Age group	Not Specified
Sex	Not Specified
Target number of participants	22
Key inclusion criteria	11 subjects and 11 controls
Key exclusion criteria	Does not meet inclusion criteria
Date of first enrolment	03/12/2001
Date of final enrolment	30/09/2005

Locations

Countries of recruitment

England
United Kingdom

Study participating centre

St George's Hospital Medical School

London
SW17 0RE
United Kingdom

Sponsor information

Record Provided by the NHSTCT Register - 2006 Update - Department of Health
Government

The Department of Health, Richmond House, 79 Whitehall
London
SW1A 2NL
United Kingdom

Phone	+44 (0)20 7307 2622
Email	dhmail@doh.gsi.org.uk
Website	http://www.dh.gov.uk/Home/fs/en

Funders

Funder type

Hospital/treatment centre

St George's Healthcare NHS Trust (UK)

No information available

No External Funding

No information available

NHS R&D Support Funding (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
Publication and dissemination plan	Not provided at time of registration
IPD sharing plan

Editorial Notes

11/10/2017: No publications found, verifying study status with principal investigator.